Sign In
Buy CELC
$88.95
-2.47 (-2.70%)
At Close: Jun 03, 2026
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:00pm, Monday, 09'th Aug 2021
Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities After follow-on offering, C
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast
07:30am, Monday, 02'nd Aug 2021
MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treat
Celcuity to Participate in the William Blair Biotech Focus Conference
04:15pm, Thursday, 08'th Jul 2021
MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pati
Celcuity Announces Pricing of Follow-on Offering
11:30pm, Monday, 28'th Jun 2021
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pat
Celcuity Announces Launch of Follow-on Offering
04:01pm, Monday, 28'th Jun 2021
MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pat
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations
09:10am, Wednesday, 09'th Jun 2021
MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating pati
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast
05:00pm, Monday, 26'th Apr 2021
MINNEAPOLIS, MN / ACCESSWIRE / April 26, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treat
Celcuity, Inc. (CELC) is on the Move, Here's Why the Trend Could be Sustainable
10:31am, Friday, 23'rd Apr 2021
Celcuity, Inc. (CELC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throu
Celcuity's (CELC) Shares March Higher, Can It Continue?
09:51am, Thursday, 15'th Apr 2021
As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).
- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected,
What's Happening With ATNF Stock And CELC Stock?
03:26pm, Monday, 12'th Apr 2021
180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the company's chief scientific of
CELC Stock: Over 80% Increase This Past Week Explanation
02:52pm, Monday, 12'th Apr 2021
The stock price of Celcuity Inc (NASDAQ: CELC) has increased by over 80% in the past 5 trading days. This is why it happened.
How A Pfizer Cancer Drug Pact Launched Celcuity Stock Into A Breakout
11:46am, Friday, 09'th Apr 2021
Celcuity broke out and soared to a nearly two-year high Friday after striking a licensing deal with Pfizer for a breast cancer treatment. Celcuity paid Pfizer $10 million in cash and stock.
What's Going On With CELC Stock And PRVB Stock Today?
09:22am, Friday, 09'th Apr 2021
Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a c
Celcuity Stock Price Increased Over 30% Pre-Market: Why It Happened
06:41am, Friday, 09'th Apr 2021
The stock price of Celcuity Inc (NASDAQ: CELC) increased by over 30% pre-market. This is why it happened.
